bendamustine hydrochloride has been researched along with Abnormal Karyotype in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonaldi, L; Branca, A; Gurrieri, C; Manni, S; Martines, A; Piazza, F; Pizzi, M; Riva, M; Scapinello, G; Semenzato, G; Trentin, L; Visentin, A | 1 |
| Bonaldi, L; Martines, A; Nabergoj, M; Piazza, F; Pizzi, M; Scapinello, G; Semenzato, G; Trentin, L; Vio, S; Visentin, A | 1 |
2 other study(ies) available for bendamustine hydrochloride and Abnormal Karyotype
| Article | Year |
|---|---|
A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib.
Topics: Abnormal Karyotype; Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Bortezomib; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Cyclin D1; Cytarabine; Drug Resistance, Neoplasm; Fatal Outcome; Gene Duplication; Genes, myc; Humans; Lymphoma, Mantle-Cell; Male; Oncogene Proteins, Fusion; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Rituximab; Translocation, Genetic | 2020 |
Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine.
Topics: Abnormal Karyotype; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Lineage; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Disease Progression; Female; Genes, Immunoglobulin; Genes, myc; Humans; Immunoglobulin Heavy Chains; Lymphocytes; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Remission Induction; Rituximab; Splenic Neoplasms; Translocation, Genetic; Trisomy | 2018 |